Brief: Acurx Announces New Ibezapolstat Data On Anti-Recurrence Mechanisms In CDI At Prominent International Conference
NASDAQ RESUMED AT 10:20 AM
Brief: Acurx Pharmaceuticals, Inc. Announces Pricing Of $15 Million Underwritten Initial Public Offering Of Common Stock
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 04:00 AM